Literature DB >> 10220831

Increased salivary interleukin-6 levels in patients with primary Sjögren's syndrome.

M Tishler1, I Yaron, I Shirazi, Y Yossipov, M Yaron.   

Abstract

This study's purpose was to evaluate salivary interleukin-6 (IL-6) levels in patients with primary Sjögren's syndrome (SS). Salivary and serum IL-6 concentrations were evaluated by ELISA in 36 patients with SS and compared with 19 patients complaining of dry mouth and with normal controls. Salivary IL-6 levels were significantly elevated (P < 0.01) in the 36 patients with SS as compared to the 19 patients with dry mouth (200.5 +/- 43.6 and 12.6 +/- 6.8 pg/ml, respectively). No significant differences were noted in the serum IL-6 levels between these two groups (105.8 +/- 17.1 and 84.8 +/- 17.1 pg/ml, respectively). Both salivary and serum IL-6 levels in the normal controls were below the level of detection of the assay. Positive correlation (r = 0.8613, P < 0.0001) was found between salivary IL-6 levels and the focus score of labial biopsies in SS patients. Elevated salivary IL-6 levels appear to be a consequence of local production and may reflect the component of salivary gland inflammation in SS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10220831     DOI: 10.1007/s002960050070

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  13 in total

Review 1.  Immunopathogenesis of Sjögren's syndrome.

Authors:  Andrea T Borchers; Stanley M Naguwa; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

2.  Comparison of N-linked Glycoproteins in Human Whole Saliva, Parotid, Submandibular, and Sublingual Glandular Secretions Identified using Hydrazide Chemistry and Mass Spectrometry.

Authors:  Prasanna Ramachandran; Pinmanee Boontheung; Eric Pang; Weihong Yan; David T Wong; Joseph A Loo
Journal:  Clin Proteomics       Date:  2008-12       Impact factor: 3.988

Review 3.  Comparative human salivary and plasma proteomes.

Authors:  J A Loo; W Yan; P Ramachandran; D T Wong
Journal:  J Dent Res       Date:  2010-08-25       Impact factor: 6.116

Review 4.  T lymphocytes in Sjögren's syndrome: contributors to and regulators of pathophysiology.

Authors:  Gikas E Katsifis; Niki M Moutsopoulos; Sharon M Wahl
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

5.  Sialometry and sialochemistry: diagnostic tools for Sjögren's syndrome.

Authors:  W W Kalk; A Vissink; F K Spijkervet; H Bootsma; C G Kallenberg; A V Nieuw Amerongen
Journal:  Ann Rheum Dis       Date:  2001-12       Impact factor: 19.103

Review 6.  Cytokines in Sjögren's syndrome.

Authors:  N Roescher; P P Tak; G G Illei
Journal:  Oral Dis       Date:  2009-06-10       Impact factor: 3.511

7.  Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome.

Authors:  Shen Hu; Jianghua Wang; Jiska Meijer; Sonya Ieong; Yongming Xie; Tianwei Yu; Hui Zhou; Sharon Henry; Arjan Vissink; Justin Pijpe; Cees Kallenberg; David Elashoff; Joseph A Loo; David T Wong
Journal:  Arthritis Rheum       Date:  2007-11

8.  Does tocilizumab contribute to elevation of rheumatoid factor and induction of paradoxical syaloadenitis in rheumatoid arthritis patients?

Authors:  Dušanka Martinović Kaliterna; Jure Aljinović; Dijana Perković; Daniela Marasović Krstulović; Ivanka Marinović; Tonko Vlak
Journal:  Wien Klin Wochenschr       Date:  2013-11-19       Impact factor: 1.704

9.  Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjögren's syndrome.

Authors:  Keiko Yoshimoto; Maiko Tanaka; Masako Kojima; Yumiko Setoyama; Hideto Kameda; Katsuya Suzuki; Kensei Tsuzaka; Yoko Ogawa; Kazuo Tsubota; Tohru Abe; Tsutomu Takeuchi
Journal:  Arthritis Res Ther       Date:  2011-10-21       Impact factor: 5.156

10.  Upregulated expression level of the growth factor, progranulin, is associated with the development of primary Sjögren's syndrome.

Authors:  Ni Zhang; Ning Yang; Qilin Chen; Feng Qiu; Xingfu Li
Journal:  Exp Ther Med       Date:  2014-09-22       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.